Table 7.
Comparison of Month 6 IOP & Glaucoma Medication Reduction in Other MIGS Studies
| Treatment n at Month 6 | Mean IOP (SD) Mean Medications (SD) | Screening | Baseline (Post Washout) | Month 6 | |
|---|---|---|---|---|---|
| VENICE† | STREAMLINE 33 | IOP | 17.10 (3.82) | 24.86 (3.05)* | 16.52 (3.63) |
| Meds | 1.90 (0.81) | 0.20 (0.48) | |||
| iStent inject W 37 | IOP | 18.20 (3.29) | 25.16 (3.41)* | 16.08 (3.19) | |
| Meds | 1.70 (0.90) | 0.40 (0.79) | |||
| Lazcano et al15 – Streamline | STREAMLINE 36 | IOP | 16.9 (3.2) | 23.2 (2.3) | 15.4 (2.1) |
| Single Site† | Meds | 2.1 (0.9) | 0.8 (1.0) | ||
| Gallardo et al22 – GEMINI† | OMNI-Phaco 134 | IOP | 17.3 (3.1) | 23.8 (3.1)** | 15.1 (3.9) |
| Meds | 1.8 (0.9) | 0.6 (1.0) | |||
| Hirsch et al23 – ROMEO | OMNI-Phaco 40 | IOP | 19.5 (3.8) | N/A | 15.1 (2.9) |
| Meds | 1.8 (1.3) | 1.1 (1.2) | |||
| Louanchi et al24 | iStent inject W-Phaco | IOP | 16.1 (2.0) | N/A | 13.0 (1.5) |
| 52 | Meds | 2.3 (0.5) | 1.8 (0.5) | ||
| Deneri et al25 | iStent inject W-Phaco | IOP | 16.08 (3.27) | N/A | 13.88 (2.57) |
| 32 | Meds | 2.69 (1.03) | 2.06 (1.34) | ||
| Hirabayashi – King26 | KDB-Phaco 42 | IOP | 17.1 (4.8) | N/A | 15.0 (no SD) |
| Meds | 2.4 (1.3) | 1.2 (1.4) | |||
| Hirabayashi – Lee27 | KDB-Phaco 97 | IOP | 17.3 (4.8) | N/A | 15.0 (3.5) |
| Meds | 2.1 (1.3) | 1.1 (1.3) | |||
| Mechleb et al28 | KDB-Phaco 28 | IOP | 18.11 (6.79) | N/A | 13.57 (2.35) |
| Meds | 2.86 (1.04) | 1.56 (1.28) |
Notes: †Screening visits for these were before IOP-lowering medication washout. *Morning average IOP at Eligibility. **Mean diurnal IOP of the entire Eligibility Day.
Abbreviations: IOP, Intraocular Pressure; Meds, Medication; SD, Standard deviation; MIGS, Microinvasive Glaucoma Surgery; IOP, Intraocular Pressure; N/A, not applicable; KDB, Kahook Dual Blade.